Abstract: A process for the production of an ethylene alpha-olefin copolymer is disclosed. The process includes polymerizing ethylene and at least one alpha-olefin by contacting the ethylene and the at least one alpha-olefin with a metallocene catalyst in at least one gas phase reactor at a reactor pressure of from 0.7 to 70 bar and a reactor temperature of from 20° C. to 150° C. to form an ethylene alpha-olefin copolymer. The resulting ethylene alpha-olefin copolymer may have a density of 0.927 g/cc or greater and environmental stress crack resistance (ESCR) of 500 hr or more when measured according to ASTM 1693/B in 10% Igepal.

Abstract: This invention relates to a process for producing an oligomeric product by the oligomerisation of at least one olefinic compound by contacting the at least one olefinic compound with an oligomerisation catalyst in an aliphatic liquid medium at a reaction temperature of at least 50° C. The catalyst comprises the combination of a source of a transition metal; and a ligating compound of the formula (R1)mX1(Y)X2(R2)n.

Abstract: The present invention relates a process for the preparation of catalytic support and the supported metallocene catalysts used in the production of ethylene homopolymers and ethylene copolymers with ?-olefins, of high and ultra high molecular weight with broad molecular weight distribution, in gas or liquid phase polymerization processes, the latter being in slurry, bulk or suspension, and the products obtained from these processes.

Abstract: Articles made of and/or including ultrahigh molecular weight polyethylene (UMWPE) having increased strength and/or wear resistance, such as high yield strength, high tensile strength, high load strength, and/or high impact strength. Some embodiments of articles made of and/or including UHMWPE having increased strength and/or wear resistance, such as that listed above, include UHMWPE having co-monomers.

Abstract: Methods of adding substituents to a benzodithiophene are disclosed. A benzodithiophene is reacted with a reagent to directly add the substituent to the benzene core of the benzodithiophene. This method eliminates steps from prior process and eliminates the need for hydrogenation, allowing for a safer and more scaleable process. The resulting benzodithiophenes are suitable for use in semiconductor polymers and have no loss of performance.

Abstract: Solid polymerizable diacetylenic monomer compositions, including compositions co-crystallized from a diversity of solvent systems under diverse cooling conditions, can exhibit diffraction patterns associated with the color development reactivities of the compositions. High reactivity compositions are disclosed and high reactivity and low reactivity phases can be identified. A low angle powder X-ray diffraction peak can indicate the presence of one or more crystal phases in a composition. A fingerprint region can exhibit fingerprint patterns of diffraction peaks associated with different reactivities. Information about polymerization of the diacetylenic monomers is disclosed using 13C nuclear magnetic resonance (“NMR”) characterization. Diacetylenic monomer compositions useful in ambient condition indicators, for example time-temperature indicators are disclosed.

Abstract: Provided is a polymer polyol which has solved problems, such as clogging in a discharge head and insufficient hardness of a resulting polyurethane foam, occurring in the production of a polyurethane foam by mechanical foaming using a conventional polymer polyol as a raw material. The present invention is a polymer polyol (A) in which polymer fine particles (JR) having an ethylenically unsaturated compound (E) as a constituent unit are contained in a polyol (PL), wherein the (PL) comprises a polyol (a) with which the average number x of moles of ethylene oxide added per active hydrogen atom and the primary hydroxidation ratio y of terminal hydroxyl groups satisfy a specific relationship, and the volume average particle diameter (R) of the (JR) is from 0.1 to 1.5 ?m.

Abstract: The present invention relates to a process for lightening the color of polyol esters by reacting polyols with linear or branched aliphatic monocarboxylic acids having 3 to 20 carbon atoms, wherein the reaction product is worked up without using adsorbents and comprises a treatment with peroxidic compounds and an immediately subsequent steam treatment with subsequent drying.

Abstract: The present invention is an aliphatic polyester resin in which a polyhydroxy acid skeleton is a main component, manufactured using a polymerization catalyst, characterized in that a specific organophosphorus compound is copolymerized in the resin. Activity of the polymerization catalyst contained in the aliphatic polyester resin of the present invention after the polymerization is well lowered and a lactide is hardly produced even by heating after the polymerization or after the manufacture.

Abstract: The invention provides a thiazolothiazole compound represented by the following Formula (I). In Formula (I), Ar1 represents a substituted or unsubstituted aromatic group; R1 represents a hydrogen atom, an alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; and n represents an integer of 0 or 1. The invention further provides a thiazolothiazole polymer having the thiazolothiazole compound as a polymerization unit thereof.

Abstract: The present invention is directed to a method for preparing renewable and relatively high purity p-xylene from biomass. For example, biomass treated to provide a fermentation feedstock is fermented with a microorganism capable of producing a C4 alcohol such as isobutanol, then sequentially dehydrating the isobutanol in the presence of a dehydration catalyst to provide a C4 alkene such as isobutylene, dimerizing the C4 alkene to a form one or more C8 alkenes such as 2,4,4-trimethylpentenes or 2,5-dimethylhexene, then dehydrocyclizing the C8 alkenes in the presence of a dehydrocyclization catalyst to selectively form renewable p-xylene in high overall yield. The p-xylene can then be oxidized to form terephthalic acid or terephthalate esters.

Abstract: The present disclosure is directed, in part, to methods of synthesizing a poly(ethylene carbonate) polymer from the reaction of ethylene oxide (EO) and carbon dioxide (CO2) in the presence of a metal complex. The present disclosure also provides novel metal complexes. In one aspect, the metal complex is of formula (I), wherein R1, R2, R3, M, X and Ring A are as defined herein.

Abstract: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first catalytic domain of an intein; D2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X(n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D1-X(n)-D2 compounds autocatalytically cyclize the X(n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.

Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.

Abstract: The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at least one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent.

Abstract: An HLA-binding peptide binding to an HLA-A type molecule is provided that includes one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 52, and not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences are amino acid sequences predicted to bind to a human HLA-A molecule using a prediction program employing an active learning experiment method shown in FIG. 1.

Abstract: The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.

Abstract: A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning from a human fetal spleen library. Sequencing of the thus-isolated cDNA and analysis of its structure revealed that the cDNA has typical characteristics of a factor belonging to the IL-6/G-CSF/MGF family. It is also found out that the culture supernatant of said sequence-transfected CHO cells shows a proliferation supporting activity towards bone marrow cells in the coexistence of kit ligand.

Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.

Abstract: A process for the production of a microparticle or a nanoparticle of a chemical compound comprising the steps of providing a solution of said chemical compound in a first liquid; providing a second liquid in which said chemical compound is insoluble or substantially insoluble; combining said liquids in a region of high shear thereby causing formation of said particles; and isolating said particles of said compound. The processing time of a coacervation style process can be reduced and the yield can be substantially increased both by control of the precipitation step which allows for desolvation step to be dispensed with leading to significant process time reduction. The invention also provides a molecular mixing unit comprising an outer body defining a mixing zone; a shear means to provide shear liquid in said mixing zone; at least one fluid inlet means for a first liquid; at least one fluid inlet means for a second liquid and a fluid outlet means.

Abstract: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Abstract: Disclosed are methods for the chromatographic separation of rebaudioside A from stevioside in glycoside solutions that are derived from stevia. The chromatographic separation may be an adsorb/desorb type of chromatographic separation or a fractionation type of chromatographic separation.

Abstract: The invention relates to nucleic acid molecules selected from the group comprising: a) nucleic acid molecules that code for a form of the polypeptide with the derived amino acid sequence according to SEQ ID No. 3, said polypeptide having a deacetylase activity; b) nucleic acid molecules that comprise the nucleotide sequence according to SEQ ID No. 1 or SEQ ID No.

Abstract: The present invention concerns a synthesis process comprising the following steps (i) reacting 3-ethyl-4-nitrobenzoic acid with thionyl chloride to produce a 3-ethyl-4-nitrobenzoic acid chloride or a 3-ethyl-4-nitrobenzoic acid anhydride from 3-ethyl-4-nitrobenzoic acid by means of water cleavage and (ii) Friedel-Crafts acylation by reacting the 3-ethyl-4-nitrobenzoic acid chloride or the 3-ethyl-4-nitrobenzoic acid anhydride with an optionally substituted aryl-H to form an optionally substituted (3-ethyl-4-nitrophenyl)-aryl-methanone. In addition the present invention concerns compounds containing (3-ethyl-4-nitrophenyl)-aryl-methanone, characterized in that the optionally substituted aryl is an optionally substituted condensed aromate.

Abstract: A process for manufacturing an oligonucleotide which comprises removing ?-eliminating phosphorus-protecting groups, in particular ?-cyanoethyl protective groups from a protected oligonucleotide, wherein said removing comprises contacting the protected oligonucleotide with an amine solution in a solvent which preferably does not consist of pyridine, wherein the conjugate acid of the amine has preferably a pKa of greater than 11.5, and wherein the concentration of the amine in the solution is less than 0.5 mole/liters.

Abstract: The object of the present invention is to provide a nucleoside or a nucleotide, or a derivative thereof, which has an unnatural base. The nucleoside and others of the present invention are characterized by having a 2-amino-6-(2-thiazolyl)purin-9-yl group or a 2-amino-6-(2-oxazolyl)purin-9-yl group as a base, wherein the 4- and/or 5-position of the thiazolyl or oxazolyl group may be substituted.

Abstract: An embodiment of a method for extracting biological material from an emulsion is described that comprises the steps of a) breaking an emulsion comprising a plurality of aqueous droplets in a continuous phase of an oil using a solvent to produce a combined aqueous-oil mixture, where the solvent disrupts the aqueous droplets which release a plurality of biological elements each immobilized on a substrate into the combined aqueous-oil mixture; b) introducing an inorganic salt to the combined aqueous-oil mixture causing a phase separation of the mixture into a first phase comprising an aqueous solution and the biological elements and a second phase comprising the solvent and the oil; c) extracting the first phase from the second phase; and d) collecting the substrate immobilized biological elements from the first phase.

Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Abstract: A method for the preparation of a sucrose-6-ester is disclosed. In a first step of the method, sucrose in a polar aprotic solvent is reacted with an organotin-based acylation promoter. The water of reaction is removed at a temperature that does not exceed about 80° C. In one aspect, the water is removed by distillation of part of the polar aprotic solvent at reduced pressure. In a second step, a carboxylic acid anhydride is added. In one aspect, the resulting reaction mixture is maintained at a temperature of 10° C. or less for a period of time sufficient to produce a sucrose-6-ester. The sucrose-6-ester can be converted to sucralose.

Abstract: A process for the production of sucrose-6-ester is disclosed. The process includes, in order, the steps of: (a) providing a first reaction mixture including sucrose, a reaction vehicle, and an organotin-based acylation promoter; (b) removing water from the first reaction mixture to afford a second reaction mixture that is substantially free from water; and (c) adding a carboxylic acid anhydride to the second reaction mixture to afford a third reaction mixture, thereby producing a sucrose-6-ester; wherein: during step (b), the removing of water includes distillation of water with the reaction vehicle using an apparatus supplying a heat flux of from 500 to 25,000 BTU/hrft2 (1577 to 78865 W/m2) selected from the group consisting of wiped film evaporators, agitated thin film evaporators, falling film evaporators and rising film evaporators.

Abstract: Processes for making photosensitive organic pigments for use in imaging members, specifically processes for making a photosensitive phthalocyanine pigments having a specific crystal form, comprising dissolving the pigment in a mixture of a haloacetic acid and alkylene halide to form a solution, precipitating the pigment by adding the solution to a non-solvent system, the solution comprised of one or more organic solvents and a small amount of water, wherein the amount of water controls the crystal form of the pigment, followed by a treatment with a halobenzene to obtain a highly photosensitive second crystal form of the pigment.

Abstract: A process for preparing compounds of the formula (I) in which R1 and R2 are as defined in the description.

Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C?NR4, and L, X, Z, R2 and R3 are as defined herein.

Abstract: The present invention provides a method of producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound in which no rapid solidification or the like occurs and generation of by-products is suppressed, thereby enabling to reduce decrease in the yield. Particularly, the present invention is a method of producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound represented by the following Formula (1): wherein the reaction between cyanuric halide compound represented by the following Formula (2): and hydroxyphenyl compound represented by the following Formula (3): is carried out by using, as the reaction solvent, a solvent containing sulfolane as the main component in the presence of a Lewis acid at an amount of 0.3 to 0.

Abstract: The present invention relates to a process for the preparation of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one; and its use in the synthesis of paliperidone.

Abstract: The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H2 or ammonium formiate, Pd/C (approx. 10%), ethanol/water, room temperature, normal pressure or also H2, Pd/C, AcOH or HCl/ethanol, 1-3 bar) in excellent yields and in an enantiomeric excess of up to 99.9%.

Abstract: Metal complexes comprising at least one polycyclic aromatic ligand and bearing at least one deuterium atom, an organic light-emitting diode comprising at least one inventive metal complex, a light-emitting layer comprising at least one inventive metal complex, an organic light-emitting diode comprising at least one inventive light-emitting layer, the use of the at least one inventive metal complex in organic light-emitting diodes, and a device selected from the group consisting of stationary visual display units such as visual display units of computers, televisions, visual display units in printers, kitchen appliances and advertising panels, illuminations, information panels and mobile visual display units such as visual display units in cellphones, laptops, digital cameras, vehicles, and destination displays on buses and trains, comprising at least one inventive organic light-emitting diode.

Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract: The present invention relates to a method for preparing Clopidogrel and its derivatives. More particularly, the present invention is a method for preparation of (S)-2-Clopidogrel and its derivatives, which are active inhibitors of platelet aggregation, from an optically active (S)-2-chlorophenyl glycine alkyl ester through hydrolysis of racemic 2-chlorophenylglycine alkyl esters using an enzyme. The present invention employs a simple procedure to prepare Clopidogrel and its derivatives. Because no chiral resolving agents are used except for a small amount of enzyme, the cost of preparation can be reduced. In addition, the present invention is suitable for synthesizing highly optical-active Clopidogrel and its derivatives on a large scale by using optically active (S)-2-chlorophenylglycine alkyl ester obtained in high yield as an intermediate, and is also environmentally friendly since no highly toxic reagents are employed.

Abstract: The present invention relates to a process for preparing 1-pyridyl-substituted pyrazoles, comprising the reaction of acetyleneketones with pyridylhydrazine derivatives to give 1-pyridyl-substituted dihydro-1H-pyrazoles, the further reaction thereof with elimination of water to give 1-pyridyl-substituted trihalomethylpyrazoles, and the further processing thereof.

Abstract: A new technical process for preparation of enantiomerically pure antifungal compounds of formula I by resolution of the racemates has been disclosed.

Abstract: The present invention provides a means which can inhibit release of I2 in production or storage of 1,3-diiodohydantoin compound, and thereby solve decrease in purity of the compound and various problems caused by I2. The present invention provides a production method for 1,3-diiodohydantoin compound comprising a step to prepare a wet body containing a 1,3-diiodohydantoin compound, and (1) a step to dry the wet body by contacting the wet body with heated gas or (2) a step to lyophilize the wet body, a storage method for 1,3-diiodohydantoin compound comprising a step to store a 1,3-diiodohydantoin compound under a temperature condition of 15° C. or lower, and a 1,3-diiodohydantoin compound wherein content of released I2 is 1% by mass or less.

Abstract: Methods for the preparation of saturated imidazolinium salts and related compounds that comprises reaction of formamidines with compounds such as dihaloethane and an optional base are disclosed. Alternatively, the imidazolinium salts and related compounds can be prepared in a one-step process without purification of the formamidine reactant. These methods make it possible to obtain numerous imidazolinium salts and related compounds under solvent-free reaction conditions and in excellent yields.

Abstract: Methods for preparation of isoindolin-1-one compounds are described.

Abstract: A dihydroindacene compound represented by the following formula (1): wherein R1 is identical or different from each other, and each denotes a hydrogen atom, alkyl which may be substituted, alkenyl which may be substituted, alkynyl which may be substituted, alkoxy which may be substituted, alkylthio which may be substituted, aryl which may be substituted, aryloxy which may be substituted, or the like; R2 to R5 are identical or different from each other, and each denote a hydrogen atom, alkyl which may be substituted, alkenyl which may be substituted, or the like; p is 0, 1, or 2; and ring structures A and B are identical or different from each other, and each denote a benzene ring which may be substituted, a thiophene ring which may be substituted, or the like.

Abstract: The present invention relates to a process for the preparation of 2,3-dihydropyran (DHP, CAS [110-87-2]) and its use in industrial chemistry.

Abstract: A process for the protection of a compound having at least one reactive functional group selected from hydroxy, mercapto, carboxyl, amino and amide, with 3,4-dihydro-2H-pyran (DHP), wherein said DHP is obtained by contacting tetrahydrofurfuryl alcohol (THFA) entrained in a carrier gas with a catalyst comprising aluminium oxide (Al2O3), and wherein the carrier gas is water vapor.

Abstract: Novel 3?-hydroxy-?5-steroid analogs possessing a contracted cyclopentane B-ring provide good inhibitory activity against Mycobacterium tuberculosis. The 5(6?7)abeo-sterol nucleus present in compounds of the invention represents a novel scaffold for the development of new antitubercular agents.

Abstract: The invention relates to a process for the oxidation of organic compounds by means of oxygen, in which, in a first step, the organic compound and at least part of the oxygen required for the oxidation are introduced into a first reaction zone which is operated isothermally and with backmixing and, in a second step, the reaction mixture from the first reaction zone is introduced into a second reaction zone which is operated adiabatically. The invention further relates to a reactor for carrying out the process, which comprises at least one isothermal reaction zone (3, 5) and an adiabatic reaction zone (7) which are arranged in a reactor shell (8), with each isothermal reaction zone (3, 5) being configured in the form of a jet loop reactor and the adiabatic reaction zone (7) being configured as a bubble column.

Abstract: Objects of the present invention are to provide a novel niobium or tantalum complex having good vapor pressure and becoming a raw material for producing a niobium- or tantalum-containing thin film by a method such as CVD method, ALD method or the like, a method for producing the same, a metal-containing thin film using the same, and a method for producing the same. The present invention relates to producing an imide complex represented by the general formula (1) by, for example, the reaction between M1(NR1)X3(L)r (2) and an alkali metal alkoxide (3): (wherein M1 represents niobium atom or tantalum atom, R1 represents an alkyl group having from 1 to 12 carbon atoms, R2 represents an alkyl group having from 2 to 13 carbon atoms, X represents halogen atom, r is 1 when L is 1,2-dimethoxyethane ligand, r is 2 when L is pyridine ligand, and M2 represents an alkali metal), and producing a niobium- or tantalum-containing thin film by using the imide complex (1) as a raw material.